Healthcare reform legislation also influences coverage, pricing and reimbursement for biopharmaceutical products. In the United States, statutes such as the Affordable Care Act and the Inflation Reduction Act, as well as other federal and state programs, establish requirements for Medicaid and Medicare drug rebates, coverage determinations, pricing transparency and other programmatic matters.
All entries for: Biologic
March 31, 2026
OSR Holdings, Inc
Negative Outlook
Bellevue, WA
1-50 employees
The Affordable Care Act and the Inflation Reduction Act, as well as other ongoing healthcare legislative and regulatory reform measures, may have a material adverse effect on our business and results of operations.
Disease Area: Oncology
Drug Type: Biologic
March 31, 2026
Nanobiotoix S.A.
Negative Outlook
Paris, France
51-200 employees
Additionally, in the United States, the Inflation Reduction Act of 2022 (IRA), enacted on August 16, 2022, includes several provisions to lower prescription drug costs for people with Medicare and reduce drug spending by the federal government. We cannot predict the ultimate content, timing or effect of any changes to the ACA, the IRA or other federal and state reform efforts, and there can be no assurance that any such health care reforms will not adversely affect our future business and financial results.
Disease Area: Oncology
Drug Type: Biologic
March 31, 2026
BioAtla Inc
Negative Outlook
San Diego, CA
51-200 employees
Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the biopharmaceutical industry and the pricing of prescription drug products.
Disease Area: Oncology
Drug Type: Biologic
March 31, 2026
Bicara Therapeutics Inc.
Neutral Outlook
Boston, MA
1-50 employees
The implementation of the IRA is currently subject to ongoing litigation that challenges the constitutionality of the IRA’s Medicare drug price negotiation program. The full impact of the IRA on our business and the pharmaceutical and healthcare industry in general is not yet known.
Disease Area: Oncology
Drug Type: Biologic
March 31, 2026
HCW Biologics Inc.
Negative Outlook
Miramar, FL
1-50 employees
Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the biopharmaceutical industry and the pricing of prescription drug products.
Disease Area: Immune Diseases, Oncology
Drug Type: Biologic
March 31, 2026
Takeda
Layoffs
Cambridge, MA
50,001+ employees
Takeda’s recently announced reorganization may affect approximately 634 U.S. employees, including 247 in Cambridge, Massachusetts effective July 1, 2026, through Dec. 31, 2027, and 387 in other states, though the total could change as staff pursue redeployment opportunities.
Disease Area: Multiple
Drug Type: Biologic, Small Molecule
March 31, 2026
Novartis/NJ
Layoffs
East Hanover, NJ
50,001+ employees
Novartis is laying off 114 employees at its East Hanover, New Jersey site, with terminations running from June 26 through Nov. 27, continuing a pattern of workforce reductions at the location over the past year.
Disease Area: Oncology, Rare Disease
Drug Type: Biologic, Small Molecule
March 30, 2026
Atkis Oncology
Neutral Outlook
Boston, MA
1-50 employees
Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and current or evolving federal policies regarding healthcare reform measures will impact the ACA or our business.
Disease Area: Oncology
Drug Type: Biologic